申请人:Beecham Group Limited
公开号:US04012407A1
公开(公告)日:1977-03-15
Pharmaceutical compositions are produced comprising as the active ingredient a compound of the formula ##STR1## or a pharmaceutically acceptable, nontoxic salt thereof or hydrate thereof, wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each hydrogen, halogen, lower alkyl or lower alkoxy, or any two of the groups R.sub.1, R.sub.2, R.sub.3 and R.sub.4, taken together with the carbon atoms to which they are joined complete a substituted or unsubstituted carbocyclic ring, and X is a bond or an oxygen atom, is combined with a pharmaceutically acceptable, nontoxic inert diluent or carrier. Those compounds wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are not all simultaneously hydrogen are novel. When X is a bond, the compounds may be prepared by reacting an appropriately substituted 3-dyanomethylene phthalide with a base and, thereafter, if desired, converting the compound to a salt. When X is an oxygen atom, the compounds may be prepared by reacting a suitably substituted benzene derivative with an activated carbonyl group having a carbanion of the formula NC--CH--R, wherein R is a carboxylic acid ester group, and thereafter, if desired, converting the compound into a salt.
制备药物组合物,其中作为活性成分的化合物为公式##STR1##或其药学上可接受的、无毒的盐或水合物,其中R.sub.1,R.sub.2,R.sub.3和R.sub.4分别为氢、卤素、低烷基或低烷氧基,或者其中两个或多个基团R.sub.1,R.sub.2,R.sub.3和R.sub.4与它们连接的碳原子一起形成取代或未取代的碳环;而X为键或氧原子,与药学上可接受的、无毒的惰性稀释剂或载体结合。其中,当R.sub.1,R.sub.2,R.sub.3和R.sub.4不同时为氢时,这些化合物是新颖的。当X为键时,可以通过将适当取代的3-腙亚甲基邻苯二甲酸酐与碱反应,然后,如果需要,将化合物转化为盐形式来制备这些化合物。当X为氧原子时,可以通过将适当取代的苯衍生物与具有公式NC-CH-R的碳负离子的活化羰基基团反应,其中R为羧酸酯基团,然后,如果需要,将化合物转化为盐形式来制备这些化合物。